Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
The objective was to estimate the incremental break-even price of QIV over TIV at a threshold of €20 000 per quality-adjusted life-year (QALY).
Source: Value in Health - Category: International Medicine & Public Health Authors: Florian Zeevat, Pascal Cr épey, F. Christiaan K. Dolk, Arjan J. Postma, Vidya N.A. Breeveld-Dwarkasing, Maarten J. Postma Source Type: research
More News: Influenza | Influenza Vaccine | International Medicine & Public Health | Netherlands Health | Vaccines